The Role of Isotretinoin Therapy for Cushing’s Disease: Results of a Prospective Study

Figure 1

Patients UFC levels (baseline and during isotretinoin therapy). Ten patients (7 to 16) were withdrawn from the study at month 6 (week 24) due to poor response whereas the remaining 6 patients (1 to 6) were given an additional 6 months (24 weeks); 2 of them (5 and 6) subsequently developed relapse of hypercortisolism. Overall, 4 (25%) patients (1 to 4) achieved sustained UFC normalization.